• Huinan Changlong Bio-Pharmacy outlined planned allocations for approximately 90% of cash and short-term investments in a Nov. 10, 2026, supplemental announcement.
• Strategic development and supply-chain integration account for 30.2%, with deployment planned for 2027-2031.
• New drug research and consistency evaluations receive 15.1%; brand promotion and clinical evidence research receive 12.6%, both for 2027-2031.
• A potential dividend reserve represents 7% for 2027-2028; the newly adopted written dividend policy sets no predetermined payout ratio.
• Cash reserves accumulated from core operating profits over two decades, rather than financing or core-business disposals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jilin Province Huinan Changlong Bio-Pharmacy Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261110-12406856), on November 10, 2026, and is solely responsible for the information contained therein.